Synergistic antioxidant urolithin A composition and application thereof in improving ovarian function direction

By combining urolithiasis A and coenzyme Q10, the problem of limited efficacy of single antioxidants has been solved, achieving significant improvement in ovarian function at low doses, including delaying ovarian aging and rebuilding ovarian function, with good safety and cost-effectiveness.

CN121015634APending Publication Date: 2025-11-28SHENZHEN PORSHEALTH BIOENGINEERING CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511446479.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-11
Publication Date
2025-11-28

AI Technical Summary

Technical Problem

Existing single antioxidants have limited effectiveness in scavenging hydroxyl free radicals and delaying ovarian aging, and they also have dose-dependent side effects, so there is a need to find natural and safe alternatives.

Method used

A synergistic antioxidant composition comprising urolithin A and coenzyme Q10 is provided, which, when combined within a certain range, produces a synergistic effect in scavenging hydroxyl radicals, and the interaction index between the two is less than 1.

Benefits of technology

It achieves good antioxidant effects at low doses, improves ovarian function, including delaying ovarian aging and rebuilding ovarian function, improves ovarian hormone levels, and has advantages in safety and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a synergistic anti-oxidation urolithin A composition and application thereof in improving the ovarian function direction, and relates to the technical field of biological medicine, and the active ingredients of the composition comprise 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10. According to the composition disclosed by the invention, the used raw materials are food-grade raw materials such as urolithin A and coenzyme Q10, and the urolithin A and the coenzyme Q10 are matched within a certain range, so that a good synergistic interaction effect can be achieved, and the composition has a good antioxidant effect; meanwhile, the composition also has the effects of effectively improving the ovarian reserve function, regulating the hormone level, improving menstruation, skin, emotion, sleep and the like at a low dosage level, and is effective and safe.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and more specifically to a synergistic antioxidant urolithin A composition and its application in improving ovarian function. Background Technology

[0002] Oxidative stress is mainly caused by the redox imbalance due to the excessive accumulation of reactive oxygen species (ROS). Its harm includes damage to cellular structures such as cell membranes, lipids, proteins, and DNA, which in turn leads to a variety of chronic diseases and acute pathological states, and may accelerate aging. ROS can be divided into two categories: free radicals and non-free radicals. Free radicals are more unstable and more reactive than non-free radicals. Reactive oxygen free radicals include hydroxyl radicals, superoxide anion radicals, peroxy radicals, alkoxy radicals, and nitrogen radicals. Among them, hydroxyl radicals (•OH) are the most active and aggressive reactive oxygen molecules (see Pan Jisheng, Deng Jiayun, Zhang Qixiang, et al. Review of the application progress of hydroxyl radical advanced oxidation technology [J]. Journal of Guangdong University of Technology, 2019, 36(02):70-77+85.). It can attack DNA, lipids, and proteins. Almost no antioxidant enzymes can directly remove it, and it can only be neutralized indirectly by non-enzymatic antioxidants such as vitamin C / E. Recent studies have found that oxidative stress can lead to ovarian endocrine dysfunction, decreased oocyte quality, and induce granulosa cell apoptosis, thereby triggering follicular atresia, which is an important cause of ovarian dysfunction. (Reference: Liang Chengcheng, Yang Hong, Qi Cong, et al. The effects of oxidative stress on decreased ovarian reserve and research progress in traditional Chinese and Western medicine antioxidant therapy [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2021, 41(07):885-889.)

[0003] As women age, oxidative stress intensifies. The ovaries, as vital reproductive endocrine organs, are susceptible to damage from reactive oxygen species, accelerating aging and leading to decreased reproductive function and hormonal imbalances. Currently, various antioxidants are being used to study and improve health problems related to oxidative stress. However, the effectiveness of single antioxidants in scavenging hydroxyl radicals and delaying ovarian aging is often limited, and they suffer from issues such as limited mechanisms of action and dose-dependent side effects (see He Yongmei, Qiu Guojun, Xu Yu, et al. Study on the safety of vitamin E use [J]. Chinese Hospital Drug Evaluation and Analysis, 2012, 12(01):69-71. DOI:10.14009 / j.issn.1672-2124.2012.01.030.). Therefore, it is necessary to find natural, safe, and effective alternative solutions. Summary of the Invention

[0004] In view of this, the present invention provides a urolithin A composition with synergistic antioxidant and ovarian function improvement and its application, in order to solve the problems of limited single antioxidant effect and high-dose safety risks in the prior art.

[0005] According to a first aspect of the invention, a synergistic antioxidant composition is provided, the composition comprising the following components in parts by weight: 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10.

[0006] Urolithin A (Uro A) is a gut microbiota metabolite of ellagitannins. Ellagantannins, as a metabolic precursor of urolithin A, are mainly found in pomegranates, strawberries, raspberries, walnuts, and red wine. Foods rich in ellagitannins are metabolized into urolithin A primarily in the colon via the stomach and small intestine. In recent years, clinical studies on urolithin A have focused on improving muscle function in middle-aged and elderly individuals, with a high clinical efficacy at a daily dose of 500-1000 mg, which has been clinically proven to have good safety at this dose. (Reference: Singh A, D'Amico D, Andreux PA, et al. Urolithin Aimproves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults[J]. CellReports Medicine, 2022, 3(5).)

[0007] Coenzyme Q10 (CoQ10), also known as ubiquinone, is the only coenzyme Q-type substance found in the human body. It is a lipid-soluble quinone compound and an important hydrogen carrier in the cellular respiratory chain, participating in oxidative phosphorylation and ATP production, and regulating the cellular redox environment. Coenzyme Q10 exists in both reduced and oxidized forms. Reduced coenzyme Q10 is easily oxidized, preventing lipid and protein peroxidation and scavenging free radicals. With the continuous advancement of clinical and epidemiological research both domestically and internationally, coenzyme Q10 has been proven to possess various health benefits, including antioxidant and free radical scavenging properties, anti-aging effects, and cardiovascular protection. Furthermore, a few clinical studies have shown that coenzyme Q10 can improve ovarian function in individuals with diminished ovarian reserve; however, the clinical dosage is high, typically 600 mg daily, and clinical studies have demonstrated good safety at this dose. (Refer to Xu Y, Nisenblat V, Lu C, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial[J]. Reproductive Biology and Endocrinology, 2018, 16(1): 29.). Low doses, such as 30mg daily, generally need to be combined with other Chinese and Western medicine methods (Refer to Tang Peipei, Guo Yinhua, Tan Yong, et al. Effects of cycle regulation combined with coenzyme Q10 on ovarian function and IVF outcome under high progesterone state in elderly DOR infertile patients - with clinical data of 30 cases[J]. Jiangsu Journal of Traditional Chinese Medicine, 2020, 52(09):35-37.).

[0008] The antioxidant composition provided by the present invention contains urolithin A and coenzyme Q10. When combined within a certain range, they can achieve a good synergistic effect, resulting in a good antioxidant effect. Moreover, the interaction index γ value of the two is less than 1.

[0009] Preferably, the active ingredient of the antioxidant composition is composed of 20 parts of urolithiasis A and 6 parts of coenzyme Q10, which are mixed evenly.

[0010] More preferably, the composition further includes pharmaceutically or food-grade excipients.

[0011] Another object of the present invention is to provide the use of the above-described composition in the preparation of products that improve ovarian function.

[0012] Preferably, the improvement of ovarian function includes delaying ovarian aging and / or restoring ovarian function and / or improving ovarian hormone levels.

[0013] Another object of the present invention is to provide a product for improving ovarian function, comprising the above-described composition.

[0014] Preferably, the product is a liquid, ointment, capsule, tablet, powder, or pill.

[0015] Beneficial effects:

[0016] 1. This invention provides a synergistic antioxidant urolithin A composition, using food-grade urolithin A and coenzyme Q10 as raw materials. When these are combined within a certain range, they produce a synergistic effect of scavenging hydroxyl free radicals, and the interaction index between the two is less than 1, confirming that the composition has good antioxidant effects.

[0017] 2. The present invention provides a urolithiasis A composition, which has a lower effective dose compared to single-component formulations, and is more advantageous in terms of safety and economy compared to existing high-dose antioxidants.

[0018] 3. The antioxidant composition of the present invention is applied to products that improve ovarian function, so that it has antioxidant effects and significantly improves ovarian reserve function and hormone levels, as well as improves menstruation, skin, mood, and sleep at low dose levels.

[0019] 4. The antioxidant composition of the present invention improves ovarian function and is safe with no side effects. Detailed Implementation

[0020] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0021] This invention discloses a synergistic antioxidant urolithin A composition and its application in improving ovarian function. All raw materials and reagents used in this invention are commercially available and their sources are not specifically limited. Unless otherwise specified, all methods involved are conventional methods and will not be described in detail here.

[0022] Example 1

[0023] The antioxidant urolithin A composition of this embodiment consists of the following active ingredient raw materials in parts by weight: 10 parts urolithin A and 40 parts coenzyme Q10.

[0024] Preparation method: Mix urolithiasis A and coenzyme Q10 thoroughly.

[0025] Example 2

[0026] The antioxidant urolithin A composition of this embodiment is composed of the following active ingredient raw materials in parts by weight: 13 parts urolithin A and 13 parts coenzyme Q10.

[0027] The preparation method is the same as in Example 1.

[0028] Example 3

[0029] The antioxidant urolithin A composition of this embodiment consists of the following active ingredient raw materials in parts by weight: 20 parts urolithin A and 6 parts coenzyme Q10.

[0030] The preparation method is the same as in Example 1.

[0031] Example 4

[0032] The antioxidant urolithin A composition of this embodiment consists of the following active ingredient raw materials in parts by weight: 100 parts of urolithin A and 6 parts of coenzyme Q10.

[0033] The preparation method is the same as in Example 1.

[0034] Comparative Example 1

[0035] This comparative antioxidant urolithin A composition consists of the following active ingredient raw materials in parts by weight: 100 parts urolithin A and 2 parts coenzyme Q10.

[0036] The preparation method is the same as in Example 1.

[0037] Comparative Example 2

[0038] This comparative antioxidant urolithin A composition consists of the following active ingredient raw materials in parts by weight: 5 parts urolithin A and 40 parts coenzyme Q10.

[0039] The preparation method is the same as in Example 1.

[0040] Comparative Example 3

[0041] This comparative antioxidant urolithin A composition consists of the following active ingredient raw materials in parts by weight: 100 parts of urolithin A.

[0042] Comparative Example 4

[0043] This comparative antioxidant urolithiasis A composition consists of the following active ingredient raw materials in parts by weight: 40 parts of coenzyme Q10.

[0044] Example 1: Detection of synergistic hydroxyl radical scavenging ability

[0045] 1. Solution preparation method

[0046] The products prepared in Examples 1-4 and Comparative Examples 1-4 were dissolved in anhydrous ethanol to prepare a stock solution of 0.1 mg / ml, which was then diluted stepwise before use.

[0047] 0.435 mmol / L Brilliant Green solution: Dissolve 0.0106 g of Brilliant Green in 50 mL of water and add it to the solution in a 37°C water bath to dissolve.

[0048] 0.5 mmol / L ferrous sulfate solution: 0.0071 g ferrous sulfate dissolved in 50 ml water.

[0049] 2. Experimental Methods

[0050] Add 1 mL of the test sample, 0.25 mL of 0.435 mmol / L Brilliant Green solution, 0.5 mL of 0.5 mmol / L FeSO4, and 0.4 mL of 3.0% (w / v) H2O2. Mix well and incubate at 37°C for 30 min. (The control group sample is ethanol; the absorbance of the control group without H2O2 is A0, and the absorbance with H2O2 is A1; the absorbance of the sample group with H2O2 is As). Centrifuge at 10000 r / min for 10 min, and measure the absorbance of the supernatant at 632 nm.

[0051] Hydroxyl radical scavenging rate (%) = (As - A1) / (A0 - A1) * 100%

[0052] The scavenging rate of hydroxyl radicals of the examples and comparative products at different concentrations was determined using the above method, and the corresponding half-maximal inhibitory concentration (IC50) was calculated. 50 (Method reference: Li Jia. Optimization of antioxidant ratio of red grape yeast, apple and pomegranate based on model [J]. Food Industry, 2025, 46(03):43-48.)

[0053] Furthermore, the synergistic effect between urolithin A and coenzyme Q10 was analyzed. The formula is: IC50add = IC50A / (P1 + R × P2), where: P1 is the proportion of urolithin A in the composition, P2 is the proportion of CoQ10 in the composition, P2 = 1 - P1; IC50A and IC50B are the half-maximal inhibitory concentrations (IC50A and IC50B), respectively; R = IC50A / IC50B.

[0054] The scavenging rates of hydroxyl radicals by the urolithiasis A and coenzyme Q10 combination were compared between IC50mix (IC50mix is ​​the half-maximal inhibitory concentration of the composition for hydroxyl radical scavenging) and IC50add (IC50add is the theoretical half-maximal inhibitory concentration of the composition for hydroxyl radical scavenging assuming no interaction). If IC50mix < IC50add, a synergistic effect is indicated. Simultaneously, the interaction index (γ) was calculated to evaluate the degree of synergy: γ = IC50Amix / IC50A + IC50Bmix / IC50B, where IC50Amix and IC50Bmix are the IC50 values ​​of components A and B after compounding, respectively, and IC50A and IC50B are the IC50 values ​​of components A and B acting individually, respectively. γ < 1 indicates a synergistic effect between components A and B; the smaller the γ value, the stronger the synergistic effect. (The calculation methods for IC50add and the interaction index γ are based on Shi Yanbin's study on the synergistic DPPH free radical scavenging effect of total flavonoids from honeysuckle and ginkgo leaves [J]. Food Research and Development, 2017, 38(05):43-46.)

[0055] 3. Experimental Results

[0056] As shown in Table 1, the combination of urolithin A and coenzyme Q10 consistently exhibited IC50mix < IC50add within the set ratio range, indicating a synergistic effect between the two. Furthermore, the interaction index γ values ​​were all less than 1, indicating a synergistic effect between urolithin A and coenzyme Q10. The order of synergistic interaction magnitude was 10:3 > 50:3 > 1:1 > 1:4 > 1:8 > 50:1. The γ value was lowest when the ratio of urolithin A to coenzyme Q10 was 10:3, indicating the best synergistic interaction in scavenging hydroxyl radicals.

[0057] Table 1. Scavenging rate of hydroxyl radicals by each combination and interactions between components.

[0058]

[0059] Example 2: In vivo antioxidant test and verification of improved ovarian function in mice

[0060] 1. Experimental Grouping

[0061] Balb / C female mice (8-10 weeks old, 45 in total) were randomly divided into 5 groups: blank control group, premature ovarian failure model group, combination drug administration experimental group of Example 1, Comparative Example 3 and Comparative Example 4, 9 mice in each group. Each group was weighed and marked and housed in separate cages.

[0062] 2. Experimental Methods and Results

[0063] Mice in the model group, Example 1, Comparative Example 3, and Comparative Example 4 were intraperitoneally injected with 100 mg / kg of cyclophosphamide for two consecutive weeks, while the blank group and control group were intraperitoneally injected with the same volume of physiological saline. They were fed continuously for 6 weeks, receiving oral gavage once daily. Examples 1, Comparative Example 3, and Comparative Example 4 were administered the corresponding composition at 41.67 mg / kg via gavage, while the model group and blank control group received the same volume of physiological saline via gavage. For the following 20 days, the blank group and model group were given 0.5% sodium carboxymethyl cellulose aqueous solution (solvent control). Mouse body weight and feed weight were measured and recorded on fixed dates (every 5 days).

[0064] Indicators for successful model establishment: decreased ovarian coefficient and irregular or disordered estrous cycles in mice; significant decrease in serum estrogen E2 / anti-Müllerian hormone (AMH) in mice; significant reduction in total number of follicles, secondary and antral follicles in mouse ovaries, and an increase in atretic follicles.

[0065] (1) Analysis of mouse ovarian coefficient and detection of estrous cycle

[0066] After the last administration, the mice were fasted for 12 hours, then anesthetized and euthanized with a 20% ursotose solution. Blood was collected from the orbital rim, and the mice were euthanized by cervical dislocation. The abdomens of the mice were dissected, and both ovaries were removed, weighed, and the ovarian coefficient was calculated using the following formula:

[0067] Ovarian coefficient (%) = bilateral ovarian weight (mg) ÷ mouse body weight (g) × 100%

[0068] For 10 consecutive days starting from model establishment and for another 10 consecutive days starting from week 4 of sample intervention, vaginal exfoliated cell smears were examined daily at 10:00 AM to observe the estrous cycle of the mice. Using a 20 μL pipette, 10 μL of physiological saline was drawn and slowly inserted into the mouse vagina approximately 0.5 cm deep. The pipette was blown 2-3 times to aspirate the saline, which was then evenly spread onto a clean glass slide, allowed to dry, and stained with H&E.

[0069] The ovarian coefficient analysis results of each group of mice are shown in Table 2. Compared with the blank group, the ovarian coefficient of the model group mice was significantly decreased (p < 0.05), indicating that cyclophosphamide treatment did indeed lead to ovarian atrophy and functional decline. The ovarian coefficient of the Example 1 group was significantly higher than that of the model group and Comparative Examples 3 and 4 (p < 0.05), indicating that the urolithin A composition provided by this invention can repair ovarian function to a certain extent, and its repair ability is better than that of urolithin A and coenzyme Q10 alone.

[0070] Table 2 Analysis of ovarian coefficients in mice of each group

[0071]

[0072] In this experiment, a normal estrous cycle was defined as one lasting 4-5 days with even distribution of cycles, while a cycle shorter than 4 days or longer than 5 days with irregular cycles was defined as an irregular cycle. The estrous cycle detection results for each group of mice are shown in Table 3. Compared with the control group, all mice in the model group were in irregular cycles, indicating that ovarian function was impaired after cyclophosphamide treatment. The proportion of normal cycles in Example 1 group was 88.33%, higher than that of the model group (0%), Comparative Example 3 (50%), and Comparative Example 4 (16.67%), indicating that the urolithin A composition provided by this invention can repair ovarian function to a certain extent, and its repair ability is superior to that of urolithin A and coenzyme Q10 alone.

[0073] Table 3 Percentage of estrous cycles in mice of each group

[0074]

[0075] In summary, compared with the blank control group, the ovarian coefficient of the model group mice was significantly reduced and the estrous cycle was completely disordered, indicating that cyclophosphamide treatment caused ovarian function decline in mice and the premature ovarian failure model was successfully established.

[0076] (2) Determination of markers of oxidative stress and inflammatory response

[0077] Ovarian tissue samples (0.15–0.2 g, right side) were placed in a 1.5 mL centrifuge tube and homogenized with 0.9% saline solution at a ratio of 1:9 (w / v) to prepare a 10% ovarian tissue homogenate. The homogenate was then centrifuged twice at 13,000 rpm for 10 minutes, discarding the precipitate and retaining the supernatant. The levels of oxidative stress markers malondialdehyde (MDA), glutathione peroxidase (GSH-PX), and inflammatory factors interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) were measured using a kit.

[0078] The results of oxidative stress marker levels are shown in Table 4. Compared with the control group, the model group showed a significant decrease in GSH-Px content and a significant increase in MDA level, indicating that cyclophosphamide treatment exacerbated oxidative stress in the mouse ovaries and disrupted the antioxidant defense system. The composition in the examples was significantly superior to the model group and comparative examples 3 and 4 in increasing glutathione peroxidase (GSH-Px) and reducing malondialdehyde (MDA) production (p < 0.05). This indicates that the urolithin A composition provided by this invention can effectively enhance the antioxidant capacity in the mouse ovaries and is significantly superior to the antioxidant effects of urolithin A and coenzyme Q10 alone.

[0079] Table 4. Levels of oxidative stress markers in the ovaries of mice in each group

[0080]

[0081] The results of inflammatory response factors are shown in Table 5. Compared with the control group, the levels of IL-1β, IL-6, and TNF-α in the model group were significantly increased (p < 0.05), indicating that cyclophosphamide treatment induced a local inflammatory response in the mouse ovary, an effect closely related to oxidative stress. The IL-1β level in the example group was significantly lower than that in the control group, model group, comparative examples 3 and 4 (p < 0.05). Simultaneously, the levels of IL-6 and TNF-α in the example group were significantly lower than those in the model group and comparative examples 3 and 4 (p < 0.05). This indicates that the urolithin A composition provided by this invention can effectively improve the inflammatory response in the mouse ovary and is significantly superior to urolithin A and coenzyme Q10 alone.

[0082] Table 5. Levels of ovarian inflammatory factors in mice of each group

[0083]

[0084] (3) Serum hormone levels

[0085] Blood was collected from the ocular venous plexus of mice, allowed to stand for 2 hours, and then centrifuged at 4000 r / min for 15 min at 4℃. The serum was separated, and the levels of anti-Müllerian hormone (AMH), estradiol (E2), follicle-stimulating hormone (FSH), and the FSH / LH ratio in the serum were detected using an ELISA kit.

[0086] The hormone levels in each group are shown in Table 6. Compared with the blank group, the AMH and E2 levels in the model group were significantly decreased (p < 0.05), while FSH and FSH / LH were significantly increased (p < 0.05). This indicates that the increased oxidative stress and reproductive toxicity caused by cyclophosphamide impair ovarian function and induce apoptosis of primordial and growing follicles in the ovary, destroy granulosa cell activity, and reduce follicle pool reserve, thereby leading to a decrease in the secretion of AMH and E2 in the ovary. FSH and FSH / LH are compensatorily increased by activating the HPO axis through the E2 negative feedback regulation mechanism. Example 1 group was significantly better than the model group, blank control group, and comparative groups 3 and 4 in increasing the levels of anti-Müllerian hormone AMH and estradiol E2. Simultaneously, the experimental group was significantly better than the model group and blank control group in reducing FSH and FSH / LH.

[0087] Table 6. Serum sex hormone levels in mice of each group

[0088]

[0089] (4) Observation of ovarian tissue

[0090] Mouse ovaries (left half) were fixed in 4% paraformaldehyde, followed by routine dehydration, clearing, paraffin embedding, sectioning, and dewaxing. Sections were stained with Mayer's hematoxylin solution for 5–7 min, washed with pure water to regain blue color, and then mounted with neutral resin after air drying. Finally, the morphological changes of the ovarian tissue were observed under a microscope.

[0091] The follicle counts in the ovarian tissue are shown in Table 7. Compared with the blank control group, the number of mature follicles decreased and the number of atretic follicles increased in the model group, indicating that cyclophosphamide treatment can disrupt the follicular homeostasis of female rat ovaries. Compared with other groups, the number of primordial follicles in Example 1 group increased, the number of mature follicles was high, and the number of atretic follicles was low, indicating that the urolithin A composition provided by this invention can effectively improve follicle survival rate and follicle development, and has a trend of being superior to urolithin A and coenzyme Q10 alone. This may be related to the good synergistic antioxidant capacity of the urolithin A composition.

[0092] Table 7. Follicle count in the ovaries of mice in each group

[0093]

[0094] This efficacy example demonstrates that the urolithin A composition provided by this invention can effectively improve oxidative stress and inflammatory responses in mouse ovarian tissue caused by cyclophosphamide treatment. It can also effectively improve the imbalance of hormone levels such as anti-Müllerian hormone (AMH), estradiol E2, follicle-stimulating hormone (FSH), and FSH / LH caused by ovarian dysfunction due to cyclophosphamide treatment, with significantly better improvement effects than urolithin A and coenzyme Q10 alone (p < 0.05). Furthermore, it also shows a trend of being superior to urolithin A and coenzyme Q10 alone in improving follicle development and survival rate in ovarian tissue.

[0095] Example 3: Clinical validation showed improvement in ovarian function and related physical conditions.

[0096] 1. Sample preparation: Hard capsules were prepared using the composition for delaying ovarian aging in Example 1 and excipients and additives available in the art, each capsule containing 400 mg (composition content approximately 62.5%).

[0097] 2. Population selection: 30 women aged 35-45 with declining ovarian function were selected.

[0098] (1) Inclusion criteria:

[0099] Women aged 35-45 years; declining ovarian function. [Diagnostic criteria for declining ovarian function: meet two of the following criteria. Refer to the second edition of "Chinese Obstetrics and Gynecology" edited by Cao Zeyi. (1) Clinical manifestations: menstrual disorders, or accompanied by infertility, or a history of embryonic arrest, or a history of spontaneous abortion, meeting one of the above criteria. (2) Biochemical parameters: on the 2nd-4th day of menstruation, measure the levels of blood hormones AMH, FSH, LH, and E2, meeting any one of the following conditions. ① FSH ≥ 10 mIU / mL, AMH < 1.1 ng / mL, meeting any one of the conditions. ② AMH ≤ 2 ng / mL, FSH / LH ≥ 2, FSH > 9 mIU / mL, meeting two of the conditions.]

[0100] (2) Testing period: The trial of health food to improve ovarian function was conducted for 3 menstrual cycles, once a day, with 2 capsules with meals.

[0101] Testing Methods: Ovarian function blood indicators (anti-Müllerian hormone AMH, estrogen E2, follicle-stimulating hormone FSH, and follicle-stimulating hormone / luteinizing hormone ratio FSH / LH) were measured on day 0 and 3 menstrual cycles after product consumption. Self-perception evaluations (menstrual cycle, sleep, skin, body, mood, and sexual function indicators) were conducted after 3 menstrual cycles of product consumption. The changes before and after product consumption were compared to determine the product's effectiveness in improving ovarian function and its safety.

[0102] 3. Results:

[0103] (1) Blood hormone levels

[0104] Table 8. Comparison of hormone levels before and after treatment in trial participants (mean x ± SD)

[0105]

[0106] Note: *P<0.05 compared with the participants before treatment.

[0107] Table 8 shows that after three menstrual cycles of consuming the product, the average AMH level increased by 0.10±0.26 ng / ml compared to when the product was not consumed, which was statistically significant (p<0.05). The E2 level also increased significantly by 29.82±70.06 pg / mL compared to when the product was not consumed (p<0.05). Meanwhile, the FSH level decreased by 0.30±5.22 mIU / mL compared to when the product was not consumed, and the FSH / LH ratio decreased by 0.73±1.76. The results indicate that the combination of urolithiasis A and coenzyme Q10 has a positive effect on improving female ovarian function.

[0108] Table 9. Overall improvement in various aspects for test subjects (N=30, %)

[0109]

[0110] Note: TOP2 = Improved + Significantly Improved

[0111] As shown in Table 9, after three menstrual cycles of product use, the improvement rates in six major areas—menstruation, sleep, skin, physical condition, mood, and sexual function—all exceeded 70%. Among these, menstrual condition, sleep, and physical condition showed the highest improvement rates, with 96.4% of participants reporting improvement after consuming the product. Skin condition was the second highest, with 92.9% of participants reporting improvement in all three areas. Mood was the next best, with 89.3% of participants reporting improvement. The proportion of participants reporting improvement in sexual function was relatively low, at 71.4%.

[0112] Table 10 Comparison of safety indicators before and after administration to test subjects (mean x ± SD)

[0113]

[0114] As can be seen from the results in Table 10, there were no significant differences in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CREA) levels before and after the test subjects took the product (P>0.05), and all were within the normal range, indicating that the urolithiasis A composition of the present invention is safe.

[0115] This efficacy example demonstrates that the urolithiasis A composition provided by this invention can effectively improve ovarian function and hormone levels in women with declining ovarian function, and also improves skin, menstruation, overall health, sexual function, sleep, and mood. No allergic reactions or other adverse reactions were observed in the subjects during the trial, indicating that the product has good safety.

[0116] In summary, the urolithin A composition provided by this invention demonstrates, through hydroxyl radical scavenging experiments, that urolithin A and coenzyme Q10 exhibit excellent synergistic antioxidant effects with an interaction index γ < 1. Furthermore, in vivo mouse experiments have verified that the urolithin A composition provided by this invention can effectively improve oxidative stress and inflammatory responses induced by cyclophosphamide treatment, with significantly better improvement effects than the single urolithin A and coenzyme Q10 group (p < 0.05), indicating the rationality and effectiveness of the combination in this invention. In addition, in vivo mouse experiments show that the urolithin A composition provided by this invention can also effectively improve the imbalance of hormone levels such as anti-Müllerian hormone (AMH), estradiol E2, follicle-stimulating hormone (FSH), and FSH / LH caused by ovarian dysfunction due to cyclophosphamide treatment, with significantly better improvement effects than the single urolithin A and coenzyme Q10 group (p < 0.05). Simultaneously, the urolithin A composition provided by this invention can also promote follicle development in ovarian tissue and improve ovarian function. Ultimately, real-person clinical studies have shown that capsules made from the urolithiasis A composition provided by this invention can significantly increase AMH and E2 levels in women with declining ovarian function (p < 0.05), effectively improving ovarian function and hormone levels, and also improving skin, menstruation, overall health, sex life, sleep, and mood. No allergic reactions or other adverse reactions were observed in the subjects during the trial, indicating that the product has good safety.

[0117] The various embodiments in this specification are described in a progressive manner, with each embodiment focusing on the differences from other embodiments. The same or similar parts between the various embodiments can be referred to each other.

[0118] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A synergistic antioxidant urolithin A composition, characterized in that, The composition consists of 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10.

2. The synergistic antioxidant urolithin A composition according to claim 1, characterized in that, The composition consists of 20 parts urolithin A and 6 parts coenzyme Q10.

3. The synergistic antioxidant urolithin A composition according to claim 1 or 2, characterized in that, The composition also includes pharmaceutically or food-grade excipients.

4. The composition according to any one of claims 1-3, characterized in that, The composition has a synergistic antioxidant effect, and the interaction index γ of the two is less than 1.

5. The use of the composition according to any one of claims 1-3 in the preparation of products that improve ovarian function.

6. The application according to claim 5, characterized in that, The improvement of ovarian function includes delaying ovarian aging and / or restoring ovarian function and / or improving ovarian hormone levels.

7. A product for improving ovarian function, characterized in that, Includes the composition according to any one of claims 1-3.

8. The product according to claim 6, characterized in that, The products are liquids, ointments, capsules, tablets, powders, and pills.